Skip Navigation

The Bing Center for Waldenström's Macroglobulinemia Treatment Team

  • The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.

    Waldenström's Macroglobulinemia Leadership

    Steven Treon, MD, PhD

    Steven P. Treon, MD, PhD, director, Bing Center for Waldenström's Macroglobulinemia
    Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's and the development of novel therapeutics. He serves on the editorial boards of Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. He has been honored with several research and academic awards, including the Robert A. Kyle Award for Waldenström's.

    Waldenström's Macroglobulinemia Physician

    Jorge Castillo, MD

    Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström's Macrobulinemia
    Castillo's clinical program runs a series of prospective clinical trials using non-chemotherapeutic regimens, and has developed several multi-institutional efforts to study Waldenström's macroglobulinemia. He serves as a member of the NCCN panel for Multiple Myeloma, Systemic Light Chain Amyloidosis and Waldenström's Macroglobulinemia. His work has been published in New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Blood.